Ligand binding of multi-chain antigen receptors and hematopoietin/cytokine receptors results in rapid activation of protein tyrosine kinase (PTK)-dependent signalling molecules such as phosphatidylinositol 3-kinase (PI 3-kinase). Co-precipitation studies have shown that Srcrelated PTK, such as Lyn, associates with the p85 regulatory subunit of PI 3-kinase via SH2 and SH3 domain binding with their cognate ligands. More recent studies have shown that the proto-oncogene product Cbl co-precipitates with p85 following engagement of cytokine and antigen receptors. As opposed to in vitro co-precipitation studies, the yeast two-hybrid screen reveals in vivo protein ± protein interactions. Using the yeast two-hybrid screen, we demonstrate an in vivo association of Lyn's SH3 and SH2 domains with the proline-rich domain of Cbl. Lyn's SH3 and SH2 domains do not interact with p85 in the yeast two-hybrid screen, as would be predicted from glutathione-S-transferase (GST) fusion protein pull-down or co-immunoprecipitation studies from whole cell lysates. However, the SH3 domain of p85 interacts with the proline-rich domain of Cbl. When yeast were transformed with catalytic Lyn, an interaction between p85's SH2 domain and Cbl occurred. From the data, we propose the following three step process of PI 3-kinase activation: (1) complexes of Lyn ± Cbl and Cbl ± p85 exist without ligand stimulation, (2) upon ligand binding, Lyn becomes active and phosphorylates Cbl, and (3) Cbl's tyrosine phosphorylated residue serves as a docking site for the SH2 domains of p85 ± thereby stabilizing the complex and activating PI 3-kinase. The yeast two-hybrid system can be used to dissect the precise mechanisms of in vivo protein ± protein interactions, including those between phosphotyrosine and SH2-containing proteins.
Ligand binding of multi-chain antigen receptors and hematopoietin/cytokine receptors results in rapid activation of protein tyrosine kinase (PTK)-dependent signalling molecules such as phosphatidylinositol 3-kinase (PI 3-kinase). Co-precipitation studies have shown that Srcrelated PTK, such as Lyn, associates with the p85 regulatory subunit of PI 3-kinase via SH2 and SH3 domain binding with their cognate ligands. More recent studies have shown that the proto-oncogene product Cbl co-precipitates with p85 following engagement of cytokine and antigen receptors. As opposed to in vitro co-precipitation studies, the yeast two-hybrid screen reveals in vivo protein ± protein interactions. Using the yeast two-hybrid screen, we demonstrate an in vivo association of Lyn's SH3 and SH2 domains with the proline-rich domain of Cbl. Lyn's SH3 and SH2 domains do not interact with p85 in the yeast two-hybrid screen, as would be predicted from glutathione-S-transferase (GST) fusion protein pull-down or co-immunoprecipitation studies from whole cell lysates. However, the SH3 domain of p85 interacts with the proline-rich domain ofIntroduction A cardinal feature of tyrosine kinase-dependent signalling cascades is the formation of signalling molecule complexes (Cantley et al., 1991) . Complex formation is coordinated by an SH2 or phosphotyrosine binding domain's recognition of a small tyrosyl phosphoprotein motif (Pawson, 1995) . Speci®c protein ± protein associations also occur through an SH3 domain's interaction with a poly-proline helix (Cohen et al., 1995) . A class of enzymatically-inactive proteins, known as adaptors, contain such SH2 and SH3 domains.
The lipid kinase, phosphatidylinositol (PI) 3-kinase, becomes activated via receptor or Src-related protein tyrosine kinases . Receptor-encoded tyrosine kinases become tyrosyl phosphorylated, and these tyrosyl phosphorylated residues may serve as a docking site for the tandem SH2 domains of the p85 subunit of PI 3-kinase. Src-related protein tyrosine kinases have been found to contain p85 in antibody or anity reagent co-precipitations, and thus, it has been postulated that the tyrosyl phosphorylated kinase is recognized by p85's SH2 domains and the kinase's SH3 domain recognizes the proline-rich domain of p85 (Pleiman et al., 1994) . The adaptor protein Cbl, when expressed as an oncoprotein, results in B cell and myeloid leukemias (Langdon et al., 1989) . Because Cbl has been found to co-precipitate with p85, cytosolic and receptor-encoded protein tyrosine kinases (Cory et al., 1995; Fukazawa et al., 1995; Hartley et al., 1995; Kim et al., 1995; Solto and Cantley, 1996) , it is possible that dysregulation of PI 3-kinase may be oncogenic.
The yeast two-hybrid system is a recently developed technique which identi®es in vivo protein ± protein interaction. The juxtaposition of a yeast DNA-binding domain with a transcriptional activation domain, facilitated by protein ± protein interaction, results in transcription of the reporter lacZ gene (Bartel et al., 1993; Chien et al., 1991) . To determine the speci®c in vivo protein ± protein interactions, we have used the yeast two-hybrid assay system with the Src-related PTK Lyn, Cbl and p85 as baits and targets.
Results
To examine the in vivo interaction of Lyn, Cbl and p85 and to identify requisite domains for interaction, we subcloned their cDNAs into the yeast expression vectors, pGBT9 and pGAD424 (Table 1) . Yeast twohybrid screening was performed bi-directionally, and most interactions were tested in at least two independent transformations. Positive interaction was determined by b-galactosidase activity observed at dierent time intervals. The data are presented in Table 2 .
Full-length Lyn interacted with full-length or the proline-rich domain of Cbl, but not with full-length or the proline-rich domain of p85. Further mapping of Lyn's domains which interacted with Cbl showed that the SH3 domain alone was not sucient for an interaction, but an interaction occurred with the SH3 and SH2 domains, with optimal results with the Lyn construct composed of the unique, SH3, and SH2 domains. A construct expressing the unique and SH2 domains of Lyn failed to interact with Cbl's prolinerich domain. Therefore, we conclude that both SH3 and SH2 domains are required for the Lyn ± Cbl interaction. The yeast two-hybrid approach corroborates the ®ndings from co-precipitation studies that both SH3 and SH2 domains were required for Fyn ± p85 or Lck ± p85 interaction (Prasad et al., 1993a,b) . Although we did not examine the cDNA for Fyn or Lck in the yeast two-hybrid assay, a phylogenetic tree shows close resemblance between Lyn and Lck in their SH2 and SH3 domains (Drebin et al., 1995) .
Since no construct of p85 interacted with any Lyn construct, we hypothesized that another adaptor molecule might be bridging Lyn with p85. One candidate adaptor molecule is Cbl. We examined whether p85 interacted with Cbl and found that p85's SH3 domain interacted with both full-length and the proline-rich domain of Cbl.
Bi-directional interactions were performed, that is, switching the bait-containing and target-containing cDNAs for Lyn, p85 and Cbl. Most of the Lyn ± Cbl interactions were weaker when Cbl was expressed in the pGAD vector. Failure to achieve bi-directional interaction does not diminish the validity of the interaction. Rather, other structural features may account for the failure to demonstrate a similar anity of interaction.
Based on the data in Table 2 , minimal components required for in vivo interactions were: (1) Lyn SH3 and SH2 domains with Cbl's proline-rich region and (2) p85's SH3 domain and Cbl's proline-rich region. To determine possible SH2-phosphotyrosine interactions between Cbl and p85, we established transformants with either full-length Lyn, non-catalytic Lyn (Lyn's unique region, SH3, and SH2 domains), or a kinaseinactive Lyn (LynD275). The presence of tyrosine kinase activity of full-length Lyn and its absence in non-catalytic Lyn or kinase-inactive Lyn, was demonstrated by anti-phosphotyrosine blotting of Lyn immunoprecipitates (Figure 1 ). Yeast were then transformed with combinations of Cbl and p85, and a three-way screen was carried out. In the presence of catalytic Lyn, full-length Cbl and full-length p85 interacted in both directions (Table 3 vs Table 2c ). (Songyang et al., 1993) , we next asked which tyrosine site provided the potential SH2 docking site. Three-way screening performed with Lyn, p85, and a protein of Cbl (`Cbl : mid'), which contains one of the two putative p85 SH2 recognition sites, Y 371 , failed to demonstrate an interaction. Three-way screening performed with Lyn, p85 and the C-terminal region of Cbl (`Cbl : end'), which contains the other putative p85 SH2 recognition site, Y
731
, demonstrated an interaction. Three-way screening of non-catalytic Lyn, p85 and Cbl did not demonstrate an interaction. These results suggest that a tri-molecular complex of Lyn-tyrosyl phosphorylated Cbl ± p85 occurs and that the likely site of phosphotyrosine-SH2 interactions lies between the SH2 domains of p85 and the Y 731 of Cbl.
Discussion
Enhanced PI 3-kinase activity is found in cells transformed by polyoma middle T, v-src and v-abl. The lipid kinase activity increases in response to a variety of ligands, which bind to receptors and rapidly activate intrinsic and cytosolic PTK. Common to both oncogenic and normal stimulation of PI 3-kinase are tyrosyl phosphorylation and protein ± protein interaction events. PI 3-kinase consists of a regulatory subunit of 85 kDa and a catalytic subunit of 110 kDa. Based on either antibody-mediated immunoprecipitation or GST fusion protein anity reagent co-puri®cation studies, it is thought that PI 3-kinase activity is regulated by p85's association with sigalling molecules. The SH2 domains of the p85 recognize a tyrosyl phosphopeptide motif, YXXM, found in receptor-PTK, integral membrane proteins such as CD28 and CD19, cytosolic substrates such as IRS-1, and polyoma Middle T (Songyang et al., 1993) . Docking of p85 to this tyrosyl phosphorylated motif leads to proximity of PI 3-kinase to the plasma membrane and to the lipid kinase's activation. Sitedirected mutagenesis of PDGFb receptor YXXM motifs and in vitro tyrosyl phosphorylated peptide studies have con®rmed this mechanism of activation (Valius and Kazlauskas, 1993) . A role for SH3 domain as a second mechanism of activation has also been suggested through the use of GST ± SH3 binding of p85 (Pleiman et al., 1994; . As a member of the Src family of PTK, Lyn has been found to co-precipitate with p85 in B cell receptor and cytokine-stimulated cells (Corey et al., 1993; Gold et al., 1992; Yamanshi et al., 1992) . GST constructs of Lyn have been found to associate with and activate PI 3-kinase ( Pleiman et al., 1994) . Lyn and other Srcrelated PTK have been found to associate with Cbl (Cory et al., 1995; Fukazawa et al., 1995) . A role for the suciency of an SH3 ± Cbl interaction has been reported in studies with a GST fusion protein of Nck's SH3 (Rivero-Lezcano et al., 1995). Clones were made by PCR ampli®cation of speci®c full-length cDNAs or cDNA regions¯anked by engineered restriction sites and ligation into corresponding restriction sites of vectors pGBT9, pGAD424 and pEG202. When not expressed in its full-length form, the protein is denoted by the sux: U, unique; 3, SH3; 2, SH2; mid, middle portion; P, proline-rich; end, C-terminal portion
Our studies on direct in vivo protein ± protein interaction among Lyn, Cbl, and p85 revealed that Lyn ± Cbl and Cbl ± p85 interactions occurred via Lyn or p85's SH3 domains and Cbl's proline-rich region. A Cbl ± p85 interaction also occurred via p85's SH2 domains and Cbl, only when a catalytically active Lyn was expressed. Thus, we propose in Figure 2 a three-step process of PI 3-kinase activation: (1) complexes of Lyn ± Cbl and Cbl ± p85 can exist without ligand stimulation (independent of protein tyrosine kinase activation); (2) upon ligand binding, Lyn becomes active and phosphorylates Cbl; (3) Cbl's tyrosine phosphorylated residue serves as a docking site for the SH2 domains of p85 ± thereby stabilizing the complex formation and activating the lipid kinase. In the yeast two-hybrid screen, Lyn's SH3 domain was not sucient to establish an interaction with Cbl's proline-rich region. Instead, Lyn's SH2 domain was required. Three possibilities could explain this requirement: (1) the SH2 domain is required for appropriate structural presentation of the SH3 domain; (2) the SH2 domain recognizes tyrosyl phosphorylated residues of Cbl; or (3) the SH2 domain recognizes some additional heretofore unappreciated peptide motif. Since yeast do not exhibit endogenous tyrosine kinase and the Lyn ± Cbl interaction was preserved by deleting Lyn's catalytic domain, it is unlikely that the Lyn ± Cbl interaction is tyrosyl dependent.
Since GST ± LynSH3 pull-down experiments which demonstrated its association and activation of PI 3-kinase were done on cell lysates, it is likely that Cbl ± p85 complexes via SH3 and proline-rich domains were pre-formed or formed in increasing frequency via SH2-phosphotyrosine interactions after receptor stimulation. Thus, the GST ± LynSH3 captured Cbl ± p85 complexes. Increased tyrosine phosphorylation may lead to either more Cbl ± p85 complexes and/or complexes with tighter binding. Since the v-cbl product contains neither the proline-rich domain nor the Y 731 XXM site, the loss of Cbl-mediated PI 3-kinase activity or the loss of a Src-related PTK ± Cbl pathway may contribute to v-cbl's transforming properties.
Our use of yeast two-hybrid screen, therefore, clari®es the role for Lyn and probably other Srcrelated protein tyrosine kinases in PI 3-kinase activation. Although the yeast two-hybrid screen cannot address the possibility that supra-physiologic concentrations of GST ± LynSH3 can stimulate the lipid kinase, an association of Lyn with p85 cannot be demonstrated under in vivo expression conditions. These studies highlight the problem of over-interpreting protein ± protein interactions based on co-precipitation methods, which are commonly used in signal transduction studies.
Materials and methods

cDNA reagents
The cDNA for human p85 was a gift of Dr Lewis Cantley (Harvard University) and the cDNA for human Cbl was a gift of Dr Wallace Langdon (University of Western Australia). The cDNA for human p56 lyn was obtained by polymerase chain reaction of reverse transcribed human B cell mRNA, as described elsewhere (Corey and Shapiro, 1994) .
Yeast two-hybrid screen
To construct the various pGBT9-bait or pGAD424-target clones, the appropriate cDNAs were ampli®ed by PCR with forward and reverse primers containing EcoRI/ . The weak interaction, denoted in our model by hatched lines, between Cbl's proline-rich region and p85's SH3 domain is strengthened by the p85's SH2 interaction with the tyrosine phosphorylated Cbl. Therefore, PI 3-kinase activity is linked to Src-related protein tyrosine kinases via an adapter molecule, such as Cbl . Cells were harvested and lysed. Proteins from lysates were immunoprecipitated with antibody against Lyn and after SDS ± PAGE, the proteins were transferred onto membrane which was blotted with monoclonal antibody against phosphotyrosine (4G10, UBI). Blots were reprobed to demonstrate equal amounts of immunoprecipitated Lyn (data not shown)
BamHI, BamHI/SalI, or EcoRI/SalI restriction sites, gel puri®ed, and cloned into the corresponding sites in the vector polylinker site. The Lyn : U32 construct resulted from a NcoI truncation of the full-length Lyn clone. The Lyn : U2 clone was a composite of an ECoRI/BamHI ampli®cation of the unique region and a BamHI/SalI ampli®cation of the SH2 region, which were cloned into the EcoRI/SalI sites of the vectors. This resulted in the addition of Gly and Ser residues between the two regions. A list of cDNAs used is provided in Table 1. The bait vector pGBT9, containing the Gal4 binding domain, and the target vector pGAD424, containing the yeast Gal4 transactivation domain, were obtained from Clontech, Inc. (Palo Alto, CA) (Bartel et al., 1993; Durfee et al., 1993) . Each cDNA fragment was ligated into both plasmid vectors. Clones were screened by PCR and/or restriction enzyme analysis, and selected clones were also screened by sequencing. Clones of interest were tested for interaction in the yeast two-hybrid screen. The yeast strain Y153 (MATa leu2-3, 112, ura3-52, trp1-901, his3-D200, ade2-101, gal4D gal80D URA3::GAL-HIS3) was used for two-way hybrid screens, having been made competent by treatment with 100 mM lithium acetate/1 M sorbitol solution. Cells were grown overnight in 250 ml YPD media (10 g/l yeast extract and 20 g/l tryptone, Difco) supplemented with 60 mg/ml adenine, 60 mg/ml ampicillin and 2% glucose. Once cells reach O.D. 600 =0.5, the cells were pelleted, washed, and resuspended in lithium acetate/sorbitol solution. Transformation involved 1 ± 2 ml of each vector clone DNA with singlestranded salmon sperm DNA as carrier, treated cells, and a 100 mM lithium acetate/40% polyethylene glycol solution in a microfuge tube for 30 min at 308C and for 15 min at 428C. The transformation mix was then plated on 100 mm Petri dishes containing SC+Leu7Trp7His7 medium supplemented with essential amino acids, 50 mg/ml ampicillin and 2% glucose. The plates were incubated at 308C for 2 ± 3 days. Leu+Trp+His+colonies were then replica-lifted onto nitrocellulose ®lters (Schleicher & Schuell, Keene, NH) and grown for an additional 2 ± 3 days on SC plates containing 2% galactose, 2% ethanol, 3% glycerol. The ®lter was lifted and placed into liquid nitrogen for 30 s to permeabilize the yeast cells. The ®lter was then screened for b-galactosidase activity by placing the ®lter colony side up onto 3MM paper saturated with Z buer and X-gal substrate (0.12%/assay). The ®lters are incubated at 378C and examined for presence or absence of blue-green colour over time.
Yeast three-way screen
The cDNAs for full length, non-catalytic, and kinaseinactive forms of Lyn were ligated into the pEG202 plasmid. The pEG202 plasmid contains a yeast ADH1 promoter upstream of the LexA binding domain, a yeast nuclear localization signal, and histidine synthetase. The SFY526 strain (MATa, 112, can1, was transformed with combinations of pEG202, pGBT9 and pGAD424 clones. For the bgalactosidase assay, X-gal was used at 0.01%/assay.
Immunoblotting
Yeast were grown overnight in SC media and 2% glucose with adenine, lysine, and ampicillin, and were diluted to an O.D. 600 =0.2, then grown for an additional 4 ± 6 h. The cells were normalized for cell number by optical density, pelleted, and lysed in buer (20 mM HEPES, pH 7.4, 1 m/ml yeast lytic enzyme, and 15 ml/ml b-glucoronidase) rocking for 45 min at 308C. Spheroblasts were obtained by microfuge at 6000 r.p.m. and pellets were suspended in cold PBS with 1% Triton, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF and 1 mM sodium vanadate. After incubation on ice for 5 min, the lysates were microfuged for 15 min at 12 000 r.p.m. The supernatants were then used for immunoprecipitation studies. Rabbit polyclonal antibody against Lyn was purchased from Santa Cruz Biotech (Santa Cruz, CA), and murine monoclonal antibody 4G10 against phosphotyrosine was purchased from UBI (Lake Placid, NY). Standard SDS ± PAGE was performed, and the gel was transferred by electroblotting onto PVDF membrane. Detection was performed using enhanced chemilluminescence (Amersham, Arlington Heights, IL).
